Postmenopozal Stronsiyum Ranelat Tedavisinden Sonra Sıçan Kalp Dokusundaki Paraoksonaz ve Aril Esteraz Aktivitesindeki Değişiklikler
Abstract
AbstractAlterations on Paraoxonase and Aryl Esterase Activities in the Rat Heart Tissue After Postmenopausal Strontium Ranelate Therapy Objective: In this study, the effect of strontium ranelate which is used in treatment of postmenopausal syndromes enhancing the bone formation on paraoxonase and aryl esterase activities was investigated in the rats with osteoporosis. Method: 28 female Wistar albino rats were used to establish experimental osteoporosis model. Experimental animals were divided into 4 groups. Each group was composed of 7 rats. The group 1 was defined as “control group”. Group 2 was the one received strontium ranelate. Group 3 underwent ovariectomy operation and did not receive any drug. Group 4 was treated with strontium ranelate for three months after three months from the ovariectomy operation. Heart tissues of the animals in each group were isolated. Paraoxonase and aryl esterase activities were investigated. The data were statistically analyzed by utilizing SPSS 16.0 and ANOVA Test. Results: In this study, paraoxonase and aryl esterase activities in groups 2, 3 and 4 were found to be lower in comparison to that of the control group (p<0.05). Conclusion: The obtained data indicate that paraoxonase and aryl esterase levels in heart tissues get reduced during the postmenopausal period upon administration of strontium ranelate. In turn, this could make the organism sensitive to the cardiovascular diseases.
References
- Tung S, Iqbal J. Evolution, aging, and osteoporosis. Ann N Y Acad Sci 2007;11162499—506.
- Zhao H, Patrick Ross F. Mechanisms of osteoclastic secretion. Ann N Y Acad Sci 2007;11161238-44.
- Crepaldi G, Romanato G, Tonin P, Maggi S. Osteoporosis and body composition. J Endocrinol Invest 2007;30:42—7.
- Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137:2507—12.
- Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-5.
- Blahos J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007;157:589—92.
- Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008;10:92-6.
- Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535-59.
- Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM. Hormone—replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001;50:319—24.
- Topçuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topçuoglu D. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 2005;205:79—86.
- Gupta G, Aronow WS. Treatment of postmenopausal osteoporosis. Compr Ther 2007;33:114-9.
- Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J 1998;19:45-52.
- Toumis S. Improvement in bone strength parameters. The
- role of strontium ranelate. J Mnsenloskelet Neuronal
- Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium
- ranelate: a new treatment for postmenopausal osteoporosis
- Akçay YD, Sagin FG, Sendağ F, Oztekin K, Sozmen EY.
- Effects of estrogen-only therapy on LDL oxidation in
- Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio
- F, Wikinski R, Schreier L. Impaired high density
- Kwok S, Selby PL, McElduff P, Laing l, Mackness B,
- Mackness Ml, Prais H, Morgan J, Yates AP, Durrington
- Fenkci IV, Serteser M, Fenkci S, Akyol AM. Effects of
- intranasal estradiol treatment on serum paraoxonase and
- Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo—
- Parmo SL, La Du BN. Paraoxonase inhibits high-density
- Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation
- of paraoxonase (PON1) activity. Biochem Pharmacol
- Eckerson HW, Wyte CM, La Du BN. The human serum
- paraoxonase/arylesterase polymorphism. Am J Hum Genet
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
- measurement with the Folin phenol reagent. J Biol Chem
- Kumru S, Aydin S, Aras A, Gursu MF, Gulcu F. Effects of
- surgical menopause and estrogen replacement therapy on
- Ercal N, Gurer—Orhan H, Aykin—Burns N. Toxic metals and
- oxidative stress part I: mechanisms involved in metal— induced oxidative damage. Curr Top Med Chem 2001;1z529—39.
- Verit FF, Celik H, Yazgan P, Erel O, Geyikli I. Paraoxonase—
- Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK.
- Expression of major HDL-associated antioxidant PON-l is gender dependent and regulated during inşammation. Free Radie Biol Med 2003;34:824—9.
- Oh HY, Kim SS, Chung HY, Yoon S. Isoşavone
- supplements exert hormonal and antioxidant effects in postmenopausal Korean women with diabetic retinopathy. J Med Food 2005;8:1—7.
Postmenopozal Stronsiyum Ranelat Tedavisinden Sonra Sıçan Kalp Dokusundaki Paraoksonaz ve Aril Esteraz Aktivitesindeki Değişiklikler
Abstract
Türkçe Özet:Amaç: Bu çalışmada deneysel osteoporoz modeli oluşturulan sıçanlarda, kemik formasyonunu arttıran post-menopozal bir ilaç olan stronsiyum ranelatın kalp dokusundaki paraoksonaz ve aril esteraz enzim aktiviteleri üzerindeki etkileri incelenmiştir. Yöntem: Çalışmada 28 adet dişi Wistar albino sıçan kullanılmış ve her bir grupta 7 hayvan olacak şekilde 4 gruba ayrılmıştır. Bu gruplar kontrol grubu (grup 1), stronsiyum ranelat grubu (grup 2), overektomi grubu (grup 3) ve overektomi uygulandıktan 3 ay sonra 3 ay boyunca stronsiyum ranelat uygulanan grup (grup 4) olmak üzere tasarlanmıştır. Tüm gruplardaki hayvanların kalp dokuları izole edilmiş ve paraoksonaz ve aril esteraz enzim aktivitelerine bakılmıştır. İstatistiksel analiz için SPSS 16.0 ve ANOVA testi kullanılmıştır. Bulgular: Yapılan çalışmada gerek paraoksonaz gerekse aril esteraz enzim aktivitelerinin grup 2, grup 3 ve grup 4\'te kontrol grubuna kıyasla düşük olduğu tespit edildi (p<0.05). Sonuç: Bulunan sonuçlar post-menopozal dönemin ve stronsiyum ranelat kullanımının kalp paraoksonaz ve aril esteraz enzim aktivitelerini azalttığını ve organizmayı kalp damar hastalıklarına duyarlı hale getirebileceğini göstermektedir.
References
- Tung S, Iqbal J. Evolution, aging, and osteoporosis. Ann N Y Acad Sci 2007;11162499—506.
- Zhao H, Patrick Ross F. Mechanisms of osteoclastic secretion. Ann N Y Acad Sci 2007;11161238-44.
- Crepaldi G, Romanato G, Tonin P, Maggi S. Osteoporosis and body composition. J Endocrinol Invest 2007;30:42—7.
- Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137:2507—12.
- Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-5.
- Blahos J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007;157:589—92.
- Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008;10:92-6.
- Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535-59.
- Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM. Hormone—replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001;50:319—24.
- Topçuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topçuoglu D. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 2005;205:79—86.
- Gupta G, Aronow WS. Treatment of postmenopausal osteoporosis. Compr Ther 2007;33:114-9.
- Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J 1998;19:45-52.
- Toumis S. Improvement in bone strength parameters. The
- role of strontium ranelate. J Mnsenloskelet Neuronal
- Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium
- ranelate: a new treatment for postmenopausal osteoporosis
- Akçay YD, Sagin FG, Sendağ F, Oztekin K, Sozmen EY.
- Effects of estrogen-only therapy on LDL oxidation in
- Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio
- F, Wikinski R, Schreier L. Impaired high density
- Kwok S, Selby PL, McElduff P, Laing l, Mackness B,
- Mackness Ml, Prais H, Morgan J, Yates AP, Durrington
- Fenkci IV, Serteser M, Fenkci S, Akyol AM. Effects of
- intranasal estradiol treatment on serum paraoxonase and
- Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo—
- Parmo SL, La Du BN. Paraoxonase inhibits high-density
- Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation
- of paraoxonase (PON1) activity. Biochem Pharmacol
- Eckerson HW, Wyte CM, La Du BN. The human serum
- paraoxonase/arylesterase polymorphism. Am J Hum Genet
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
- measurement with the Folin phenol reagent. J Biol Chem
- Kumru S, Aydin S, Aras A, Gursu MF, Gulcu F. Effects of
- surgical menopause and estrogen replacement therapy on
- Ercal N, Gurer—Orhan H, Aykin—Burns N. Toxic metals and
- oxidative stress part I: mechanisms involved in metal— induced oxidative damage. Curr Top Med Chem 2001;1z529—39.
- Verit FF, Celik H, Yazgan P, Erel O, Geyikli I. Paraoxonase—
- Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK.
- Expression of major HDL-associated antioxidant PON-l is gender dependent and regulated during inşammation. Free Radie Biol Med 2003;34:824—9.
- Oh HY, Kim SS, Chung HY, Yoon S. Isoşavone
- supplements exert hormonal and antioxidant effects in postmenopausal Korean women with diabetic retinopathy. J Med Food 2005;8:1—7.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | September 1, 2008 |
| Submission Date | June 13, 2014 |
| Published in Issue | Year 2008 Volume: 1 Issue: 3 |
Cite
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.